ORCHPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 33/100 — Quality 27 · Valuation 0 · Momentum 100
| Share price | ₹1,046.60 |
| Market cap | ₹5,136 Cr |
| P/E ratio | 250.0 |
| P/B ratio | 4.0 |
| ROE | 40.5% |
| ROCE | 2.1% |
| Book value | ₹253.98 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹811 Cr | ₹21 Cr | 5.0% |
| 2025 | ₹922 Cr | ₹100 Cr | 13.0% |
| 2024 | ₹819 Cr | ₹92 Cr | 14.0% |
| 2023 | ₹666 Cr | ₹46 Cr | 13.0% |
| 2022 | ₹560 Cr | ₹-2 Cr | 10.0% |
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limit